期刊文献+

脱氢表雄酮抑制骨吸收的作用机制 被引量:8

Inhibition mechanism of bone resorption by dehydroepiandrosterone
下载PDF
导出
摘要 目的 研究脱氢表雄酮 (DHEA)治疗绝经后骨质疏松的作用机制。方法 体外分离和培养成骨细胞和破骨细胞 ,在有或无成骨细胞存在的条件下 ,观察 10 - 7mol·L- 1 的DHEA对破骨细胞骨吸收作用的影响 ;经DHEA作用 1,2 ,3d后 ,半定量RT PCR测定护骨素 核因子κB受体活化因子配基 (OPG RANKL)的mRNA水平。结果  10 - 7mol·L- 1 的DHEA能明显增加成骨细胞OPG RANKL的mRNA比值 (P <0 0 1) ;当成骨细胞存在时 ,DHEA可以减少骨吸收陷窝的数目 (P <0 0 5 )和面积 (P <0 0 1)。结论 DHEA只有在成骨细胞存在时可以抑制破骨细胞的骨吸收作用 ,该作用可能通过间接调节成骨细胞OPG RANKL的转录而介导。 OBJECTIVE: To investigate the action mechanism of dehydroepiandrosterone in postmenopausal osteoporosis therapy. METHODS: Osteoblast (OB) and osteoclast (OC) were isolated and cultured, then the action of dehydroepiandrosterone (10-7 mol&middotL-1) on bone resorption of OC in the presence or absence of OB was observed. The number and area of absorption lacuna of cattle slice were measured. The level of OPG/RANKL mRNA of OB cultured with DHEA was determined semiquantitatively. RESULTS: DHEA apparently increased the ratio of OPG/RANKL mRNA (P < 0.01) in OBs in the presence of OBs, and decreased the number (P < 0.05) and area (P < 0.01) of the absorption lacuna of specula. CONCLUSION: Only in the presence of OB, can DHEA inhibit the bone resorption of OC, which may be mediated by OPG/RANKL of OB.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2004年第6期429-431,共3页 Chinese Pharmaceutical Journal
基金 上海市科技发展基金 (0 0 40 190 61)
关键词 脱氢表雄酮 成骨细胞 破骨细胞 骨吸收 护骨素 核因子κB受体活化因子配基 Absorption Cell culture Diseases Drug products Hormones RNA
  • 相关文献

参考文献11

  • 1Lamberts SW,van den Beld AW,van der Lely AJ.The endocrinology of aging [J].Science,1997,278:419.
  • 2Inoue S,Urano T,Ogawa S.Molecular cloning of rat efp:expression and regulation in primary osteoblasts[J].Biochem Biophys Res Commun,1999,261(2):412.
  • 3Kameda T,Mano H,Kumegawa M.Techniques for purification of rabbit osteoclasts and analysis of their functions [J].Nippon Yakurigaku Zasshi ,1997,109(2):75.
  • 4Lindunger A,Mackay CA,EK-RYlander B.Histochemistry and biochemistry of tartrate-resistant acid phosphatase and Tartrate-resistant acid adenosine triphosphatase in bone,bone marrow and spleen:impilcations for osteoclast ontogeny[J].Bone Miner,1990,10:109.
  • 5Arnett TR,Dempster DW.A comparative study of disaggregted chick and rat osteoclasts in vitro:effects of calcitonin and prostaglandins[J].Endocrinology,1987,120:602.
  • 6Lacey D,Timms E,Tan H,et al.Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J].Cell,1998,93:165.
  • 7Wong B,RhoJJ,Arronet J,etal.TRANCE is anovel ligand of the tumor necrosis factor receptor family that activates C-Jun N-termind kinase in T cell[J].J Biol Chem,1997,272:25190.
  • 8Anderson D,Maraskovsky E,Billingsley W,et al.A homologue of the TNF receptor and its ligand enhance T cell growth and dendritic cell function[J].Nature,1997,390:175.
  • 9Kong Y,Yoshida H,Sarosi L,et al.OPGL is a key regulator of osteoclastogenesis,lymphocyte development and lymph node organogenesis[J].Nature,1999,397:315.
  • 10Yasuda H,Dhima N,Nakagawa N,et al.Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE RANK [J].Proc Natl Acad Sci USA,1998,95:3597.

同被引文献74

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部